Mannkind reported $18.89M in Sales Revenues for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Adma Biologics ADMA:US $ 33.9M 4.8M
Biocryst Pharmaceuticals BCRX:US $ 65.53M 15.61M
Chemocentryx CCXI:US $ 11.76M 6.3M
Dynavax Technologies DVAX:US $ 256.46M 142.47M
Eli Lilly And LLY:US $ 6488M 1322M
Halozyme Therapeutics HALO:US $ 152.36M 35.09M
Immunogen IMGN:US $ 14.16M 23.92M
Insmed INSM:US $ 65.22M 12.11M
JAZZ PHA JAZZ:US $ 932.88M 119.16M
Karyopharm Therapeutics KPTI:US $ 39.68M 7.99M
Macrogenics MGNX:US $ 26.01M 14.91M
Mannkind MNKD:US $ 18.89M 6.9M
Merk MRK:US $ 14593M 1308M
Novavax NVAX:US $ 185.92M 518.05M
Novo Nordisk A Fs NVO:US $ 41265M 766M
Peregrine Pharmaceuticals PPHM:US $ 31.23M 0.28M
Pfizer PFE:US $ 27742M 2081M
Xencor XNCR:US $ 30.18M 55.32M